Real-World data sought on nivolumab for bladder cancer after surgery
NCT ID NCT05779592
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to see if nivolumab's benefits seen in clinical trials hold up in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab
What this could lead to
If successful, this study could confirm that nivolumab is effective and safe in everyday clinical settings for preventing cancer recurrence after surgery.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It only includes Japanese patients, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution
City, State, Japan